PDCD1 and non-small cell lung carcinoma: The anti‐PD‐1 monoclonal antibody cemiplimab was investigated as frontline monotherapy for advanced NSCLC with PD‐L1 TPS ≥ 50% in the global Phase III EMPOWER‐Lung 1 trial (NCT03088540) [20].